Mesencephalic complex I deficiency does not correlate with parkinsonism in mitochondrial DNA maintenance disorders

Eino J H Palin1, Anders Paetau, Anu Suomalainen

  • 1Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland. eino.palin@helsinki.fi

Insights

Mitochondrial DNA maintenance disorders cause neuron damage in the substantia nigra, but complex I deficiency doesn't explain Parkinson's disease. Neuron loss in the substantia nigra correlates with Parkinson's symptoms in these genetic disorders.

Area of Science:

  • Neuroscience
  • Genetics
  • Mitochondrial Biology

Background:

  • Recessive Parkinson's disease genetics implicate mitochondrial dysfunction.
  • Mitochondrial DNA maintenance disorders can cause neurodegeneration and respiratory chain defects.
  • Parkinsonism is linked to mitochondrial DNA polymerase gamma defects, but not all mutations cause it.

Purpose of the Study:

  • Investigate the specificity of neurological manifestations in mitochondrial DNA maintenance disorders.
  • Examine mesencephalic neuropathology in patients with DNA polymerase gamma or Twinkle defects.
  • Determine the role of complex I deficiency in parkinsonism associated with these disorders.

Main Methods:

  • Studied mesencephalic neuropathology in patients with mitochondrial DNA maintenance disorders.
  • Analyzed substantia nigra and oculomotor nucleus in patients with DNA polymerase gamma or Twinkle defects.
  • Assessed respiratory chain enzyme activity, particularly complex I.

Main Results:

  • All patients showed neuronopathy in the substantia nigra, most severe in DNA polymerase gamma-associated parkinsonism.
  • Substantia nigra exhibited decreased respiratory chain complex I in all patients, irrespective of parkinsonism.
  • Neuron count in the substantia nigra correlated with parkinsonism severity, not complex I deficiency.

Conclusions:

  • Complex I deficiency is a general consequence of mitochondrial DNA maintenance defects.
  • Substantia nigra neuron loss, not complex I defect, correlates with parkinsonism in these disorders.
  • The specific neurological outcome depends on factors beyond general mitochondrial dysfunction.

Related Concept Videos

Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Mitochondrial Precursor Proteins01:39

Mitochondrial Precursor Proteins

Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70  chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial precursors...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...